Version 1
: Received: 11 September 2023 / Approved: 12 September 2023 / Online: 13 September 2023 (05:33:42 CEST)
How to cite:
Palacka, P.; Svobodová, A.; Skokanová, L.; Obertová, J.; Rejleková, K.; Babeľa, R.; Mego, M.; Vulganová, M.; Pechan, J. Factors Associated with Humoral Immune Response Following the Third Dose of the BNT162b2 Received by Employees at a Health–Care Facility. Preprints2023, 2023090842. https://doi.org/10.20944/preprints202309.0842.v1
Palacka, P.; Svobodová, A.; Skokanová, L.; Obertová, J.; Rejleková, K.; Babeľa, R.; Mego, M.; Vulganová, M.; Pechan, J. Factors Associated with Humoral Immune Response Following the Third Dose of the BNT162b2 Received by Employees at a Health–Care Facility. Preprints 2023, 2023090842. https://doi.org/10.20944/preprints202309.0842.v1
Palacka, P.; Svobodová, A.; Skokanová, L.; Obertová, J.; Rejleková, K.; Babeľa, R.; Mego, M.; Vulganová, M.; Pechan, J. Factors Associated with Humoral Immune Response Following the Third Dose of the BNT162b2 Received by Employees at a Health–Care Facility. Preprints2023, 2023090842. https://doi.org/10.20944/preprints202309.0842.v1
APA Style
Palacka, P., Svobodová, A., Skokanová, L., Obertová, J., Rejleková, K., Babeľa, R., Mego, M., Vulganová, M., & Pechan, J. (2023). Factors Associated with Humoral Immune Response Following the Third Dose of the BNT162b2 Received by Employees at a Health–Care Facility. Preprints. https://doi.org/10.20944/preprints202309.0842.v1
Chicago/Turabian Style
Palacka, P., Martina Vulganová and Juraj Pechan. 2023 "Factors Associated with Humoral Immune Response Following the Third Dose of the BNT162b2 Received by Employees at a Health–Care Facility" Preprints. https://doi.org/10.20944/preprints202309.0842.v1
Abstract
Background: BNT162b2 represents the authorized mRNA vaccine against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS–CoV–2) causing Covid–19. Methods: We conducted a prospective, single–center observational study with 273 employees of a medical facility to determine the efficacy and safety of the BNT162b2 third dose in relation to sex and BMI, and explore the possible determinants of neutralizing IgG and 25–hydroxy (25–OH) vitamin D levels. Results: At the median follow–up of 4.7 months, 38 of the participants had Covid–19 following vaccination. The incidence of adverse events (AEs) was significantly higher in females vs. males (p < 0.0108) and subjects with a high BMI of ≥ 30 kg/m2 vs. low BMI (p < 0.0117). The values of IgG were significantly enhanced in males vs. females (p < 0.0004), participants with high BMI vs. low BMI (p < 0.0003), a high number of ≥3 AEs vs. low number of AEs (p < 0.0003), and following infection with Covid–19 vs. without Covid–19 (p < 0.0005). Multivariate analysis (MVA) showed sex, BMI, number of AEs, and Covid-19 to be of predictive significance. On the contrary, 25–OH vitamin D concentrations in individuals with high vs. low BMI were significantly reduced (p < 0.0144) but this was not evident in MVA. Conclusions: This study confirmed the high efficacy of BNT162b2 in real–world scenario and revealed that its safety was affected by sex and BMI. Higher IgG levels suggesting better protection against infection were present in males, participants with high BMI, a high frequency of AEs, and those who overcame Covid-19 following vaccination.
Keywords
BNT162b2; efficacy; safety; neutralizing IgG antibodies; 25–hydroxyl vitamin D
Subject
Medicine and Pharmacology, Medicine and Pharmacology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
